September 22, 2022
New design same issue
As much as GLP-1 therapy is changing the diabetes treatment paradigm insulin remains a cornerstone of that regimen. While GLP-1’s remain highly profitable and continue to see market share gains, thank you very much obesity. Insulin has become a boring commodity were price trumps performance. The two biggest innovations in insulin came when Sanofi launched Lantus which at the time was the first and only long-acting insulin. The other was the introduction of insulin analogues. Both of these events happened years ago and little if any innovation has been seen since.
Novo Nordisk is trying to . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.
